TWiPO Host Dr. Timothy Cripe, with co-hosts Dr. Nilay Shah and Dr. Bhuvana Setty welcome Dr. Damon Reed, Director of the Adolescent and Young Adult Program at Moffitt Cancer Center and Leader of the Pediatric Cancer Foundation's pediatric phase I consortium, the Sunshine Project. Dr. Reed shares his view points on how we can improve and accelerate the current trajectory with regard to pediatric therapy development.
Entries Tagged as 'sarcoma'
October 17th, 2016 · Comments
Tags: families · cancer risk · cancer · children · pediatric cancer · childhood cancer · drug development · neuroblastoma · medulloblastoma · sarcoma · research · brain tumor · immunotherapy · clinical trials · Advancement in Cancer Research
October 6th, 2016 · Comments
TWIPO hosts Dr. Timothy Cripe and Dr. Nilay Shah (Nationwide Children's Hospital) along with guest host Dr. Ryan Roberts (Nationwide Children's Hospital), interview Dr. Elizabeth Lawlor who is a Professor of Pediatric Oncology at University of Michigan and the Director of the Cancer Biology Training Program at University of Michigan Health System. Dr. Lawlor, a Ewing Sarcoma specialist, discusses new approaches to the cellular eco-system of tumors and provides commentary on the growing landscape for women in science.
TWiPO #19 ~ More on Hedgehog signaling, brain tumor risk from cell phone use, and FDA approval of cancer drugs
February 10th, 2014 · Comments
October 30, 2011
Several just-published papers in the literature relate to recent podcast episodes, and host Dr. Tim Cripe and co-host Dr. Lionel Chow review these interesting developments.
0:55 Hedgehog Signaling: Recent papers discussing this pathway in neuroblastoma and rhabdomyosarcoma are discussed, with implications for treatment in these tumor types with itraconozole.
6:40 Cell phone and brain tumor risk: The controversy concerning criticism by the Environmental Health Trust of a study showing that cell phone use does not increase risk of brain tumors in children is explored.
Accelerated approval of cancer drugs by the FDA and implications for pediatric cancers.
15:30 Brentuximab for two types of lymphoma
21:20 Vemurafenib for melanoma
28:30 Crizotinib for non-small cell lung cancer (and potential use in neuroblastoma)
42:30 Response to email regarding personalized medicine TWiPO episode #17 and lab blog for Dr Charles Keller at OHSU
Pediatr Blood Cancer. 2011 Dec 1;57(6):930-8. doi: 10.1002/pbc.23174. Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report from the Children's Oncology Group.
Int J Oncol. 2011 Oct;39(4):899-906. doi: 10.3892/ijo.2011.1076. Pharmacological inhibition of the Hedgehog pathway preventshuman rhabdomyosarcoma cell growth.
Cancer Lett. 2011 Nov 28;310(2):222-31. Inhibition of the sonic hedgehog pathway by cyplopaminereduces the CD133+/CD15+ cell compartment and the in vitrotumorigenic capability of neuroblastoma cells.
Cell Phone Study Was Flawed, Say Some Experts by Roxanne Nelson Medscape Oncology News.
The JNCI Study by Aydin et al on Risk of Childhood Brain Cancer from Cellphone Use Reveals Serious Health Problems, Environmental Health Trust.
N Engl J Med. 2010 Nov 4;363(19):1812-21. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
FDA Approves Brentuximab for Two Lymphomas By: ELIZABETH MECHCATIE, Oncology Report Digital Network.
Clin Cancer Res. 2011 Oct 15;17(20):6428-36. Brentuximab Vedotin (SGN-35).
FDA Approves Vemurafenib for Advanced Melanoma. By: JANE SALODOF MACNEIL, Oncology Report Digital Network.
N Engl J Med. 2011 Jun 30;364(26):2507-16. Improved survival with vemurafenib in melanoma with BRAFV600E mutation.
N Engl J Med. 2011 Jun 30;364(26):2547-8. Been there, not done that--melanoma in the age of molecular therapy. http://www.ncbi.nlm.nih.gov/pubmed/21639809
Biochem J. 2011 Aug 15. Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.
N Engl J Med. 2010 Oct 28;363(18):1693-703. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Nature. 2007 Aug 2;448(7153):561-6. Epub 2007 Jul 11. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Science. 1994 Mar 4;263(5151):1281-4. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.
February 10th, 2014 · Comments
October 18, 2011
Host Dr. Tim Cripe and co-host Dr. Lionel Chow welcome special guest Dr. Jeff Toretsky on TWiPO to discuss his clinical and research interest in Ewing's sarcoma. Dr. Toretsky explains the challenges of developing a clinical grade drug from a small molecule for a specific target such as EWS-FLI1. The small market for a disease like Ewing's creates formidable hurdles for researchers, yet Dr. Toretsky is driven on by the question "If I don't do this, who will?" (17:54 mins)
Dr. Jeff Toretsky is Professor of Oncology and Pediatrics at Georgetown University. He graduated with BS in Biochemistry from University of Wisconsin, Madison, WI, and recieved his MD from University of Minnesota, Minneapolis, MN. He completed fellowship training at the NCI Pediatric Branch.
Please send any questions or comments to email@example.com
February 10th, 2014 · Comments
October 07, 2011
Dr. Tim Cripe and co-hosts Dr. Lionel Chow and Dr. Lars Wagner welcome special guest Dr. Stephen Lessnick for an in-depth discussion on the progress to date in understanding the genetics of Ewing's sarcoma. The challenges of interpreting the gene expression data as well as the ethics of collecting tumor specimens for research purposes are also explored. Dr.Stephen Lessnick is a Professor of Pediatrics and Oncological Sciences at the University of Utah, where he also serves as an Attending Physician in Pediatric Hematology/Oncology at Primary Children's Medical Center in Salt Lake City, UT. He received his PhD in Molecular Biology from UCLA in 1994, and his MD from UCLA in 1996, followed by a residency at Children's Hospital in Boston, and a fellowship at the Dana-Farber Cancer Institute and Children's Hospital. Currently, Dr. Lessnick is the Director of the Center for Children's Cancer Research at Huntsman Cancer Institute, a Jon and Karen Huntsman Presidential Professor in Cancer Research at the University of Utah, and is the Vice Chair for Biology of the Bone Tumor Committee in the Children's Oncology Group. Please send questions or comments to firstname.lastname@example.org